This timeline illustrates the Guerbet Group's growth and major innovations.
1901 : Invention of Lipiodol®.
- Marcel Guerbet develops an iodized oil, Lipiodol®. Its opacifying properties, discovered in 1918, made it the first iodinated contrast medium.
1926 : Birth of the Laboratory
- Marcel Guerbet and his son André set up a chemical and pharmaceutical production site in Saint-Ouen. New contrast agents are used in uro-angiography, bronchography and hysterosalpingography.
1972 : An international dimension
- Guerbet inaugurates its first international subsidiary in Brazil in 1972.
1980 : Lipiodol® in interventional radiology
- The first chemoembolization procedures are performed in Japan using Lipiodol® Ultra-Fluid to treat patients suffering from hepatocellular carcinoma.
1987 : Acquisition of Simafex (fine chemicals) in 1987.
1989 : Launch of Dotarem® in MRI in France.
1993 : New products added to the MRI range: Lumirem® (1993), Xenetix® (1994, X-rays) and Endorem® (1995).
2006 : An international dimension
After opening three new European affiliates in Spain, Switzerland (1987), and Austria (1996), Guerbet Spa is launched in Italy (2000).
Guerbet continues with international expansion by strengthening its presence in Asia. The Japanese affiliate, which opened in 1978, is followed by South Korea (1998), Hong-Kong (2000), and Taiwan (1999). In 2002, Guerbet becomes established in the USA.
In 2006, Guerbet launches innovation with a polypropylene softbag for Xenetix® (ScanBag® by Xenetix®).
2013 : Dotarem® and Lipiodol®
- FDA approves Dotarem® and grants Orphan Drug designation to Lipiodol® for patients with hepatocellular carcinoma. Dotarem® is the first macrocyclic and ionic gadolinium-based contrast agent in the USA.
2015 : Acquisition of Mallinckrodt's contrast media and delivery systems business
- Guerbet acquires Mallinckrodt’s contrast media and delivery systems business (“CMDS”), creating a new global leader in medical imaging solutions and services.
2020 : David Hale appointed as CEO of the Guerbet group.
2022: Launch of Elucirem™ in the US, Go Direct in India and China.
2023: Intrasense joins the Guerbet Group
2023: Marketing authorization for Elucirem™ (Gadopiclenol) is obtained in the European Union
2024: Strategic partnership between Guerbet and Nuclidium in radiotheranostics